Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With Axitinib in Advanced Mucosal Melanoma
NCT03941795Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in mucosal melanoma (MM) (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03941795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941795.